Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma.

ABSTRACT:

Background

Gastroesophageal adenocarcinoma (GOA) has poor clinical outcomes and lacks reliable blood markers. Here we present circulating tumour DNA (ctDNA) as an emerging biomarker.

Methods

Forty patients (17 palliative and 23 curative) were followed by serial plasma monitoring. Primary tumour DNA was analysed by targeted next-generation sequencing to identify somatic single-nucleotide variants (SNVs), and Nanostring nCounter^® to detect copy number alterations (CNAs). Patient-specific SNVs and CNA amplifications (CNA^amp) were analysed in plasma using digital droplet PCR and quantitative PCR, respectively.

Results

Thirty-five patients (13 palliative, 22 curative) had ≥1 SNVs and/or CNA^amp detected in primary tumour DNA suitable for tra

SUBMITTER: Openshaw MR 

PROVIDER: S-EPMC7555811 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature